Dynavax Melanoma Trial

CONDITION

Cancer

GENDER

Both males and females

AGE GROUP

From 18

to 70 years

STATUS

Completed

This trial is designed to evaluate the safety, tolerability, and preliminary efficacy of intra-tumour injections of SD-101 in combination with intravenous Keytruda (pembrolizumab) in patients with metastatic melanoma.

Patients can have progressed on prior treatment with Keytruda or other anti-PD1 therapy or can have not yet received Keytruda/other anti-PD1 therapy.  More information can be found here. 

 

CONTACT DETAILS

Clinical Trial Site: Nil
Phone Number: (08) 9242 7640 Email: info@affinityresearch.com.au Location: 95 Monash Avenue, Nedlands Western Australia, Australia

Studies Contact Form

Approved By: Bellberry Limited              

Clinical Trial Registry Link: Click Here


Notice: Function WP_Scripts::add was called incorrectly. The script with the handle "gforms_recaptcha_frontend" was enqueued with dependencies that are not registered: gforms_recaptcha_recaptcha. Please see Debugging in WordPress for more information. (This message was added in version 6.9.1.) in /srv/users/australianclinicaltrials/apps/australianclinicaltrials/public/wp-includes/functions.php on line 6260